Six-Month Patency of Long Carotid Bypass Grafts Constructed with In-Body Tissue Architecture-Induced Small-Diameter Biotubes in a Goat Model
This study investigated the long-term patency of regenerative Biotube grafts and discusses their feasibility as an alternative to autologous vein grafts for peripheral artery disease. Six Biotubes with a diameter of 4 mm were autologously fabricated in recipients using in vivo tissue engineering (in-body tissue architecture) technology and implanted as carotid artery bypass grafts in a goat model. All six grafts remained patent at 6 months despite exceeding 10 cm in length, demonstrating their biocompatibility and durability. Histological analysis revealed neointima formation, endothelialization, and minimal inflammation. However, in one goat, a graft developed stenosis, while another showed dilatation. These findings demonstrate the use of Biotubes as a viable option for peripheral vascular reconstruction as tissue-engineered vascular grafts. However, further optimization is needed to address emerging issues with their use, such as stenosis and aneurysm formation, to improve long-term patency.
Authors
- Kazuki Mori (ORCID: https://orcid.org/0000-0001-8608-7888)
- Takashi Shuto (ORCID: https://orcid.org/0000-0002-7150-4519)
- Tadashi Umeno (ORCID: https://orcid.org/0000-0003-0258-5471)
- Ryosuke Iwai (ORCID: https://orcid.org/0000-0001-9771-9959)
- Shinji Miyamoto (ORCID: https://orcid.org/0000-0002-4972-0717)
- Takayuki Kawashima (ORCID: https://orcid.org/0000-0003-1631-8497)
- Tsutomu TAJIKAWA (ORCID: https://orcid.org/0000-0001-5304-9703)
- Li Teng (ORCID: https://orcid.org/0000-0002-4929-7461)
- Yasuhide Nakayama (ORCID: https://orcid.org/0000-0002-4466-3629)
Institutions
- Okayama University of Science (JP)
- Oita University (JP)
- Kansai University (JP)
Publication Details
- Journal
- Bioengineering
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3390/bioengineering12030260
- Primary Topic
- Electrospun Nanofibers in Biomedical Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Kaken Pharmaceutical